QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement
Tuesday, May 16, 2023
QSAM Biosciences and RLS announced a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children.
The RLS agreement allows for the rapid and efficient preparation of CycloSam® doses, under strict industry quality control systems, for patient administration in the current and future clinical trials with an option to expand to commercial scale if CycloSam® is ultimately approved by the FDA.
RLS partnership with the talented management team at QSAM will support the important clinical trials. This announcement, deepens commitment to build a world-class CDMO and clinical trial business and serves as a trusted, reliable partner for companies like QSAM developing the next-generation of nuclear therapies.
Samarium-153 (Sm-153) is a beta-emitting radioisotope that carries radiation designed and intended to disrupt tumour cell metabolism and cause cancer cell death. With a short 46-hour radiation half-life, Sm-153, in combination with the bone-seeking chelant DOTMP that significantly limits unwanted off-target migration of radiation to nearby healthy tissues, represents a potentially highly effective bone cancer treatment.
